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CliniCal artiCle
EvidEncE-basEd medicine relies on high-quality re-search to determine whether medical interventions are of benefit to patients. Randomized controlled 
trials (RCTs) provide the strongest evidence on the ef-
fectiveness of medical interventions.3 However, RCTs can 
only shape the evidence landscape through efficient trial 
completion and publication of results in the medical litera-
ture. Early trial discontinuation and nonpublication pose 
major issues for health care research and patient care due 
to the significant waste of resources surrounding uncom-
pleted trials. In addition, unpublished data can distort and 
bias the literature and lead to underinformed decisions on 
medical interventions that can even lead to patient harm.4
A recent study by Chapman and colleagues aimed to 
assess the discontinuation and nonpublication rate of sur-
gical RCTs.6 They found that from 395 surgical trials there 
was a discontinuation rate of 21% and a nonpublication 
rate of 34%. However, that study only assessed 10 neuro-
surgical trials, which does not provide a robust assessment 
of the subspecialty’s trial landscape. Neurosurgery, in 
particular, suffers from the difficulties in trial design that 
plague surgical RCTs, including the study of low-caseload 
diseases in which slow recruitment or small sample size 
may fail to result in well-matched groups following ran-
domization.9 The problem of small sample sizes in neuro-
surgery is well known and was reported as “endemic” in 
the text Guiding Neurosurgery by Evidence (2006).17 An-
other issue facing neurosurgical trialists is increased risk 
abbreviations CONSORT = Consolidated Standards of Reporting Trials; IF = impact factor; PI = principal investigator; RCT = randomized controlled trial. 
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obJeCtive This study aimed to determine the trial discontinuation and publication rate of randomized controlled trials 
(RCTs) in neurosurgery.
MethoDs Trials registered from 2000 to 2012 were identified on the website clinicaltrials.gov using a range of key 
words related to neurosurgery. Any trials that were actively recruiting or had unknown status were excluded. Included 
trials were assessed for whether they were discontinued early on the clinicaltrials.gov database; this included trials iden-
tified as withdrawn, suspended, or terminated in the database. For included trials, a range of parameters was identified 
including the subspecialty, primary country, study start date, type of intervention, number of centers, and funding status. 
Subsequently, a systematic search for published peer-reviewed articles was undertaken. For trials that were discontin-
ued early or were found to be unpublished, principal investigators were sent a querying email.
resUlts Sixty-four neurosurgical trials fulfilled our inclusion criteria. Of these 64, 26.6% were discontinued early, with 
slow or insufficient recruitment cited as the major reason (57%). Of the 47 completed trials, 14 (30%) remained unpub-
lished. Discontinued trials showed a statistically significant higher chance of remaining unpublished (88%) compared with 
completed trials (p = 0.0002). Industry-funded trials had a higher discontinuation rate (31%) compared with non–industry-
funded trials (23%), but this result did not reach significance (p = 0.57). Reporting of primary outcome measures was 
complete in 20 (61%) of 33 trials. For secondary outcome measures, complete reporting occurred in only 11 (33.3%) of 
33.
ConClUsions More than a fifth (26.6%) of neurosurgical RCTs are discontinued early and almost a third of those that 
are completed remain unpublished. This result highlights significant waste of financial resources and clinical data.
https://thejns.org/doi/abs/10.3171/2016.8.JNS16765
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of patient dropout from studies that require long follow-up 
times.17 Alongside the logistical difficulties, neurosurgical 
RCTs also face ethical hurdles, such as difficulty obtaining 
consent from patients with impaired consciousness. While 
sham operations are considered by many to be an impor-
tant control component used in neurosurgical RCTs, they 
are also a controversial area, as has been demonstrated by 
opposition to sham operations in the field of Parkinson’s 
disease research.7 Due to these difficulties, we believed it 
was important to gain a greater understanding of the dis-
continuation and publication rates of neurosurgery trials.
The introduction of the trial registry clinicaltrials.org 
has helped provide an open access repository of registered 
trials and create more transparency concerning clinical 
trial data. Much effort has recently focused on trying to 
identify factors associated with early discontinuation and 
nonpublication of clinical trials, including the role of in-
dustry participation.8 Coupled with this effort, initiatives 
such as the Alltrials campaign (www.alltrials.net) seek to 
decrease the loss of data from RCTs and provide a frame-
work by which we can acquire better evidence on clinical 
interventions while reducing resource wastage.4 Another 
major influence on the field has been made by the Consoli-
dated Standards of Reporting Trials (CONSORT) Group 
who have produced minimum reporting standards for 
RCTs.2 This study aims to systematically review registered 
RCTs in neurosurgery and quantify the rates of trial dis-
continuation and publication.
Methods
A neurosurgical RCT was defined as any Phase 3 or 4 
trial that assessed a procedure involving an incision to the 
head or spine and/or had a neurosurgeon as its principal 
investigator (PI). A list of key words to identify neurosur-
gical trials were devised using PubReMiner and informal 
literature searches to obtain MESH terms. The following 
list of key words were used to probe the clinicaltrials.gov 
database: “neurosurgery” OR “craniotomy” OR “discec-
tomy” OR “laminectomy” OR “shunt” OR “external ven-
tricular drain” OR “epilepsy surgery” OR “vagus nerve 
stimulator” OR “functional neurosurgery” OR “aneurysm 
clipping” OR “aneurysm surgery” OR “glioblastoma” OR 
“meningioma” OR “brain metastasis” OR “skull base” OR 
“deep brain stimulation.”
Within our search parameters, a “first received” date 
range of January 1, 2000, to December 31, 2012, was stip-
ulated, which allowed for completed trials to be published. 
This date range applied to when clinicaltrials.gov received 
the trial information rather than the trial start date. Trials 
identified as completed, withdrawn, suspended, or termi-
nated were included within the study. A completed trial 
was defined as a clinical study that ended as planned and 
participants were no longer being treated or examined. 
Any trials that were actively recruiting or had unknown 
status were excluded. Following screening for status, 2 
independent reviewers (A.B.G. and A.A.B.J.) determined 
whether trials were an RCT design and whether it fulfilled 
our criteria for a neurosurgical trial. Any disagreement 
was settled with discussion. For included trials a range 
of parameters were identified, including the neurosurgi-
cal subspecialty, primary country, study start date, type 
of intervention (procedure, device, drug, other), number 
of centers (single or multicenter trial), and funding status 
(industry or nonindustry funded).
All included studies were then assessed for whether 
they had been published in a peer-reviewed journal. Clini-
caltrials.gov trial profiles were assessed for published re-
sults and the trial and PI names were searched in PubMed. 
Trials that were found to have been published had further 
data points extracted from the publication, including: date 
of publication, 2014 journal impact factor (IF), and com-
pleteness of trial outcome measurements compared with 
those defined on the trial registration page at clinicaltrials.
gov. For trials that were discontinued or unpublished, trial 
PIs were contacted to ascertain the reasons behind this 
status. All PIs were also contacted to ascertain approxi-
mate costs for running the included trials.
statistical analysis
Two main end points for the trials were defined: discon-
tinuation and nonpublication. Discontinuation was defined 
as any trial that stopped early and this included trials iden-
tified on clinicaltrials.gov as “withdrawn,” “terminated,” 
or “suspended.” Nonpublication was defined as any com-
pleted trial that did not have a published research article in 
a peer-reviewed journal. Figure generation and statistical 
analysis were achieved using Microsoft Office Excel and 
GraphPad Prism 6. Two-tailed chi-square tests were used 
to compare the different groups. A p value ≤ 0.05 was con-
sidered statistically significant.
results
A total of 723 trials were identified during the primary 
search phase using the predefined key words. From these 
trials, 307 trials were excluded because they were either 
actively recruiting or had unknown status. Of the remain-
ing 416 trials, 64 met our definition of a neurosurgical RCT 
(Table 1). Figure 1 demonstrates the search process and 
reasons for trial exclusion. Among the included studies, 29 
(45%) were industry funded. The subspecialties included 
were spinal (27%), functional and epilepsy (19%), neu-
rooncology (17%), anesthesia and perioperative care (14%), 
CSF (9%), neurovascular (9%), and neurotrauma (5%). 
The studies assessed devices in 39% of cases, followed 
by drugs in 33% and procedures in 28%. The US was the 
primary country in more than half (53%) of the trials, fol-
lowed by France (8%) and Canada (6%).
Discontinued trials
Of the included trials, 17 were terminated early, giv-
ing our cohort of trials a discontinuation rate of 26.6%. Of 
the 17 terminated trials, 14 (82%) provided a reason for 
discontinuation either on the clinicaltrials.gov website or 
by email from the trial PI. The main cause (57%) of early 
termination was slow or insufficient patient recruitment. 
Table 2 highlights the other major reasons for early termi-
nation of the clinical trials. Of the discontinued trials, 2 
were published in peer-reviewed articles, giving the cohort 
a nonpublication rate of 88%. A further 3 trials made their 
results available through clinicaltrials.gov.
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table 1. table summarizing included studies
Study  
Title Subspecialty Intervention Funding Center
Start 
Date 
(Mo-Yr)
End  
Date 
(Mo-Yr) Status
Surgery vs stereotactic radiosurgery in the treatment of 
single brain metastasis: a randomized trial
Neurooncology Procedure Nonindustry Single Jan-98 Dec-05 Completed
Hypothermia during intracranial aneurysm surgery trial Neurovascular Procedure Nonindustry Single Feb-00 Unknown Completed
Surgical vs nonsurgical treatment for spinal stenosis Spinal Procedure Nonindustry Single Sep-00 Dec-07 Completed
COGNIShunt system for Alzheimer’s disease CSF Device Industry Single Jan-01 Oct-04 Completed
Dexanabinol in severe traumatic brain injury Neurotrauma Drug Industry Single Jan-01 Sep-04 Completed
STN-stimulation versus best medical treatment in ad-
vanced PD
Functional & 
epilepsy
Procedure Nonindustry Multi Jan-01 Jan-05 Completed
Performance of the hedrocel cervical fusion device Spinal Device Industry Multi Dec-01 Jan-09 Discontinued
Radiosurgery with or without whole-brain radiation therapy 
in treating patients with brain metastases
Neurooncology Procedure Nonindustry Multi Dec-01 Oct-14 Completed
Decompressive craniectomy in malignant middle cerebral 
artery infarcts
Neurovascular Procedure Nonindustry Single Dec-01 May-16 Discontinued
rhBMP-2/CRM/CD HORIZON spinal system pivotal study Spinal Device Industry Multi Mar-02 Feb-10 Completed
Phase I deep brain stimulation (DBS) vs best medical 
therapy (BMT) trial
Functional & 
epilepsy
Device Nonindustry Multi Apr-02 Oct-08 Completed
Phase II subthalamic nucleus (STN) vs globus pallidus 
(GPi) trial
Functional & 
epilepsy
Device Industry Multi Apr-02 Apr-09 Completed
A trial comparing radiosurgery with surgery for solitary 
brain metastases
Neurooncology Procedure Nonindustry Single Dec-02 May-09 Completed
A clinical study of the Dynesys spinal system Spinal Device Industry Multi Mar-03 Dec-15 Discontinued
Duragen vs Duraguard in Chiari surgery CSF Drug Nonindustry Single Apr-03 Apr-10 Completed
MAVERICK total disc replacement - pivotal study Spinal Device Industry Multi Apr-03 Nov-10 Completed
Economic medical evaluation of treatment of the neuro-
pathic pain rebel by cortical stimulation
Functional & 
epilepsy
Device Nonindustry Multi Aug-03 Dec-07 Completed
Surgery vs radiosurgery to treat metastatic brain tumors Neurooncology Procedure Nonindustry Single Dec-03 Nov-05 Completed
The PRECISE trial: study of IL13-PE38QQR compared to 
GLIADEL wafer in patients with recurrent glioblastoma 
multiforme
Neurooncology Drug Industry Multi Feb-04 Mar-07 Completed
Impact of ventricular catheter used with antimicrobial 
agents on patients with a ventricular catheter
CSF Device Nonindustry Single Apr-04 Jun-09 Completed
PCM cervical disc system Spinal Device Industry Multi Jan-05 Aug-14 Completed
High light and low light dose PDT in glioma Neurooncology Drug Nonindustry Single Mar-05 Mar-06 Completed
CONCEPT: crossover efficacy pain trial in motor cortex 
stimulation for intractable neuropathic pain
Functional & 
epilepsy
Device Industry Multi Jun-05 Mar-08 Discontinued
Double-blind, multicenter study to assess the efficacy of 
bilateral pallidal stimulation in patients with medically 
refractory primary cervical dystonia
Functional & 
epilepsy
Device Industry Multi Jul-05 Apr-08 Completed
STIMEP: assessment of subthalamic nucleus stimulation 
in drug resistant epilepsy
Functional & 
epilepsy
Device Nonindustry Multi Sep-05 Mar-10 Discontinued
Clinical efficacy of in-situ thrombolysis in case of intraven-
tricular haemorraghia by aneurysm rupture
Neurovascular Procedure Nonindustry Single Oct-05 Dec-09 Completed
RNS system pivotal study Functional & 
epilepsy
Device Industry Multi Dec-05 May-11 Completed
Study comparing best medical practice with or without 
VNS therapy in pharmacoresistant partial epilepsy 
patients
Functional & 
epilepsy
Device Industry Multi Feb-06 Jul-08 Discontinued
Effects of erythropoietin on cerebral vascular dysfunction 
and anemia in traumatic brain injury
Neurotrauma Drug Nonindustry Single Apr-06 Mar-13 Completed
Discrete hypothermia in the management of traumatic 
brain injury
Neurotrauma Device Nonindustry Single Jul-06 Oct-08 Completed
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table 1. table summarizing included studies
Study  
Title Subspecialty Intervention Funding Center
Start 
Date 
(Mo-Yr)
End  
Date 
(Mo-Yr) Status
Effect of NovoTTF-100A in recurrent glioblastoma multi-
forme (GBM)
Neurooncology Device Industry Multi Sep-06 Jan-11 Completed
Safety and effectiveness study of the TOPS system, a total 
posterior arthroplasty implant designed to alleviate pain 
resulting from moderate to severe lumbar stenosis
Spinal Device Industry Multi Sep-06 Unknown Completed
Effect of Parecoxib on post-craniotomy pain Anesthesia & 
periop care
Drug Nonindustry Single Sep-06 Dec-08 Completed
Herniectomy vs herniectomy with a spinal stabilization 
system for the treatment of complex disc disease
Spinal Device Industry Multi Nov-06 Jun-13 Completed
Simvastatin in aneurysmal subarachnoid haemorrhage 
(STASH) a multicentre randomised controlled clinical 
trial
Neurovascular Drug Nonindustry Multi Jan-07 Feb-14 Completed
Randomized study of anular repair with the Xclose tissue 
repair system
Spinal Procedure Industry Multi Mar-07 Jan-12 Completed
Neural stem cell preserving brain radiation therapy & 
stereotactic radiosurgery in patients with 1-6 brain 
metastases
Neurooncology Procedure Nonindustry Single Mar-07 Jun-09 Discontinued
Nimotuzumab in adults with glioblastoma multiforme Neurooncology Drug Industry Multi Aug-07 Jan-12 Completed
Aprepitant with dexamethasone versus ondansetron with 
dexamethasone for PONV prophylaxis in patients hav-
ing craniotomy
Anesthesia & 
periop care
Drug Industry Single Sep-07 Jun-09 Completed
Preemptive analgesia for postlaminectomy Anesthesia & 
periop care
Drug Nonindustry Single Sep-07 Dec-07 Completed
Effects of X-STOP vs laminectomy study Spinal Device Industry Single Nov-07 Nov-11 Discontinued
Clazosentan in reducing vasospasm-related morbidity and 
all-cause mortality in adult patients with aneurysmal 
subarachnoid hemorrhage treated by surgical clipping
Neurovascular Drug Industry Multi Nov-07 Jul-10 Completed
The Tilburg vasospasm study Neurovascular Procedure Nonindustry Single Dec-07 Jun-09 Discontinued
Anesthesiological strategies in elective craniotomy Anesthesia & 
periop care
Drug Nonindustry Multi Dec-07 Dec-09 Completed
Dexmedetomidine effects on microelectrode recording in 
deep brain stimulation
Functional & 
epilepsy
Drug Nonindustry Single Jan-08 Jan-12 Discontinued
A multicenter study of hippocampal electrical stimulation 
(HS) in mesial temporal lobe epilepsy
Functional & 
epilepsy
Procedure Nonindustry Multi Jan-08 Mar-12 Discontinued
Wallis interspinous dynamic stability system for lumbar 
disc herniation: a prospective study
Spinal Procedure Nonindustry Single Jul-08 Oct-12 Completed
Pre-lemniscal radiation deep brain stimulation for ET Functional & 
epilepsy
Procedure Nonindustry Single Oct-08 Unknown Discontinued
Efficacy and safety of AP 12009 in patients with recur-
rent or refractory anaplastic astrocytoma or secondary 
glioblastoma
Neurooncology Drug Industry Multi Dec-08 Jun-12 Discontinued
Comparison of propofol to precedex with propofol for 
emergence and recovery in patients having craniotomy 
surgery
Anesthesia & 
periop care
Drug Nonindustry Single Feb-09 Feb-10 Completed
Study of epidural steroid injection (ESI) vs minimally 
invasive lumbar decompression (MILD) in patients with 
symptomatic lumbar central canal stenosis
Spinal Procedure Industry Single Aug-09 May-13 Completed
Clinical trial to evaluate safety and efficacy of Hyalospine 
in lumbar laminectomy or laminotomy
Spinal Device Nonindustry Multi Nov-09 Nov-12 Completed
Spinal cord stimulation with precision system vs reopera-
tion for failed back surgery syndrome
Spinal Device Industry Multi Feb-10 May-13 Discontinued
CONTINUED ON PAGE 5 »
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The neurosurgical subspecialty with the highest discon-
tinuation rate was functional and epilepsy neurosurgery 
(50%) followed by neurovascular (33%) and spinal (29%; 
Table 3). Trials focusing on drugs had a lower discontinu-
ation rate (14%) compared with trials focusing on devices 
(32%) and procedures (33%). Industry-funded trials had a 
nonsignificantly (p = 0.57) higher termination rate (31%) 
compared with nonindustry-funded trials (23%). The 
table 1. table summarizing included studies
Study  
Title Subspecialty Intervention Funding Center
Start 
Date 
(Mo-Yr)
End  
Date 
(Mo-Yr) Status
Safety and effectiveness of the Adherus dural sealant sys-
tem when used as a dural sealant in cranial procedures
CSF Device Industry Multi Jun-10 Jan-13 Completed
A study to evaluate the safety and effectiveness of EVICEL 
as an adjunct to sutured dural repair
CSF Drug Industry Multi Jul-10 Oct-11 Completed
Surgery and whole brain radiotherapy (RT) vs whole brain 
radiotherapy (RT) and radiosurgery for 1-3 resectable 
brain metastases
Neurooncology Procedure Nonindustry Single Jul-10 Jul-10 Discontinued
TASALL - TachoSil against liquor leak CSF Procedure Industry Multi Apr-11 Jun-13 Completed
Comparison of dexmedetomidin and remifentanil for the ef-
fect on airway reflex and hemodynamic response during 
emergence in patients undergoing craniotomy
Anesthesia & 
periop care
Drug Nonindustry Single May-11 Sep-12 Completed
Evaluation of fusion rate of anterior cervical discectomy 
and fusion (ACDF) using Cervios and Bonion
Spinal Device Nonindustry Single Nov-11 Aug-13 Completed
The PRIORi-T Trial - prospective randomized investigation 
of radiofrequency targeted vertebral augmentation
Spinal Device Industry Multi Nov-11 Unknown Discontinued
Reduction bleeding in laminectomy with double doses of 
tranexamic acid
Spinal Drug Nonindustry Single Jun-12 Dec-13 Completed
Diclofenac administered before skull operations reduces 
the severity of headache after the intervention
Anesthesia & 
periop care
Drug Nonindustry Single Dec-12 Apr-13 Completed
Effects of perioperative pregabalin for post-craniotomy 
pain
Anesthesia & 
periop care
Drug Industry Single Aug-13 Unknown Discontinued
Correlation of measured and calculated serum osmolality 
during hyperosmolar drugs infusion in patients after 
craniotomy
Anesthesia & 
periop care
Drug Nonindustry Single Jan-14 Jun-14 Completed
ET = essential tremor; PD = Parkinson’s disease; PDT = photodynamic therapy; PONV = postoperative nausea and vomiting; RNS = responsive neurostimulation; STN 
= subthalamic nucleus; VNS = vagus nerve stimulation.
» CONTINUED FROM PAGE 4
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number of involved centers also did not affect the trial dis-
continuation rate, with single-center trials having a non-
significantly (p = 0.82) higher discontinuation rate (28%) 
compared with multicenter trials (25%). Temporal changes 
of trial discontinuation rate demonstrated an increase from 
16.7% in 2002–2005 up to 33.3% in 2010–2014 (Fig. 2).
A total of 12 responses were received regarding trial 
costs. From these responses, 2 responders did not know 
their trial costs, 3 advised that their trials did not receive 
funding and could not provide a cost, and 7 provided an es-
timated cost. Of these 7 studies with cost data, 2 were dis-
continued early. The average cost across the 7 studies was 
$2,593,086, with a range of $22,400–$11,000,000. The 2 
discontinued trials had a cumulative cost of $314,400.
Completed trials
Of the 47 completed trials, we found 33 published re-
search articles in peer-reviewed journals, giving the cohort 
a nonpublication rate of 30%. Completed trials had a sig-
nificantly lower nonpublication rate compared with discon-
tinued trials (88%; p = 0.0002). Of the 14 unpublished tri-
als, 4 provided some data on the clinicaltrials.gov registry. 
Of the 3 PIs who responded to our email, 2 of their stud-
ies had not been published because of a failure to accrue 
sufficient numbers of participants. In 1 of these cases, the 
manuscript had been submitted for publication but rejected 
for this reason. A manuscript was in preparation for the 
final unpublished trial. Trials assessing CSF management 
(50%) and spinal (42%) and neurooncological (38%) in-
terventions had the highest nonpublication rates (Table 4). 
table 2. Data regarding the reasons for trial termination
Reason for Termination No. of Trials* (%)
Slow or insufficient enrollment 8 (57)
Administrative issues 3 (21)
Procedural/technical challenges 2 (14)
Patient preconceptions inhibited randomization 1 (7)
New research priorities 1 (7)
One arm evidently superior—unethical to continue 1 (7)
* There were 14 total trials included; 3 trials did not have information on the 
reason for discontinuation. Note that some trials cited multiple reasons for 
noncompletion and as a result have been coded multiple times.
Fig. 2. Bar chart demonstrating temporal change in trial discontinuation from 1998 to 2014.
table 3. Details of the differing discontinuation rates based on 
a range of parameters
Parameter Total Discontinued (%)
Neurosurgical subspecialty
 Anesthesia & periop care 9 1 (11)
 CSF 6 0 (0)
 Functional & epilepsy 12 6 (50)
 Neurooncology 11 3 (27)
 Neurotrauma 3 0 (0)
 Neurovascular 6 2 (33)
 Spinal 17 5 (29)
Intervention type
 Device 25 8 (32)
 Drug 21 3 (14)
 Procedure 18 6 (33)
Funding status
 Industry 29 9 (31)
 Nonindustry 35 8 (23)
No. of centers
 Multicenter 32 8 (25)
 Single center 32 9 (28)
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Multicenter trials had a higher nonpublication rate at 35% 
compared with single-center trials (25%), but this did not 
reach statistical significance (p = 0.59). Industry- and non–
industry-funded trials had the same nonpublication rate of 
30% (p = 0.98). Trials assessing devices had the highest 
nonpublication rate (41%), followed by procedures (33%) 
and drugs (17%).
For the published articles, the median time from the 
study start date to publication was 7.6 years, with a range 
of 1.8–17.5 years. Articles were published in journals with 
a median 2014 IF of 4.9, with a range of no IF to 55.8. The 
study populations reported in the research articles ranged 
from 19 to 1147, with a median population of 169 patients. 
Primary outcome measures were completely reported in 
61% of the trials while the reporting of secondary outcome 
measures was more scarce, with only 33.3% of the trials 
reporting these measures (Fig. 3). Data on outcome mea-
sure reporting in individual neurosurgical subspecialties is 
shown in Fig. 4. This figure highlights that neurosurgical 
trials focusing on anesthesia/perioperative care and func-
tional operations had the best reporting record of registered 
primary and secondary outcome measures.
Discussion
This study demonstrated that more than one-fifth of 
neurosurgical RCTs are discontinued early and almost 
a third of those that are completed remain unpublished. 
These data highlight that neurosurgery suffers from the 
same waste of resources and ethical concerns surround-
ing trial discontinuation and nonpublication that have been 
described and discussed in the literature.10
To our knowledge, this study is the most comprehensive 
assessment of these issues within the neurosurgical litera-
ture. Two recent studies have examined the issue of sur-
gical RCT discontinuation and publication outcome with 
differing methodologies and outcomes. Chapman and col-
leagues used clinicaltrials.gov as a registration platform 
and found a discontinuation rate of 21%.6 This study only 
evaluated 10 neurosurgical trials, however, which consti-
tuted only 3% of the studied cohort, limiting the general-
izability of the results to the neurosurgical literature. Con-
versely, Rosenthal et al. used trial protocols approved by 6 
ethics committees as the resource to follow up RCTs.18 The 
study found that 43% of the 127 surgical RCTs had been 
discontinued early. Rosenthal et al.’s study did not identify 
what proportion of the trials was neurosurgical. Compar-
ing our study to the 2 above, we believe our methodologies 
Fig. 3. Pie charts showing the reporting of (a) primary outcome measures and (b) secondary outcome measures for published 
trials. “Unregistered” means no outcome measures were uploaded to the clinicaltrials.gov database.
table 4. Details on the differing nonpublication rates based on 
a range of parameters
Parameter Completed Nonpublished (%)
Neurosurgical subspecialty
 Anesthesia & periop care 8 2 (25)
 CSF 6 3 (50)
 Functional & epilepsy 6 1 (17)
 Neurooncology 8 3 (38)
 Neurotrauma 3 0 (0)
 Neurovascular 4 0 (0)
 Spinal 12 5 (42)
Intervention type
 Device 17 7 (41)
 Drug 18 3 (17)
 Procedure 12 4 (33)
Funding status
 Industry 20 6 (30)
 Nonindustry 27 8 (30)
No. of centers
 Multicenter 23 8 (35)
 Single center 24 6 (25)
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were more aligned with the study of Chapman et al.; our 
finding of a 26.6% rate of discontinued neurosurgical tri-
als was higher than that of the general surgical cohort in 
the Chapman et al. study. The differences in the assessed 
interventions between the studies may explain the higher 
neurosurgical trial discontinuation rate. Within our study, 
pharmacological interventions were assessed in a third 
of the trials compared with almost double (63%) those in 
the Chapman et al. study. Although neither our study nor 
Chapman’s study identified significant differences in dis-
continuation rates between these cohorts, a larger study 
investigating 863 RCTs found that trials assessing invasive 
treatments had higher discontinuation rates than those as-
sessing noninvasive treatments.18
There is a wide range of reasons for why a clinical trial 
may be discontinued early, ranging from unexpected harm, 
to futility, to recruitment or funding issues. The premature 
termination of a clinical trial may also be related to pre-
specified criteria and should not always be considered a 
failure. The most commonly cited reason for discontinua-
tion of neurosurgical RCTs was slow or insufficient enrol-
ment. The importance of slow or insufficient enrolment is 
not a problem limited to trials in neurosurgery and a num-
ber of other studies have found it to be the primary reason 
for early disconuation.6,12,18 Poor recruitment, although still 
a major source of discontinuation in medical trials, appears 
to be less pronounced. Rosenthal et al. found that surgi-
cal trials were significantly more likely to be discontinued 
due to poor recruitment compared with medical trials.18 
Our study had the highest percentage of trial discontinu-
ation due to poor recruitment (57%) compared with both 
the Chapman et al. (44%) and Rosenthal et al. (43%) stud-
ies.6,18 This is likely due to a range of causes, including low 
caseloads in neurosurgery and issues with capacity in acute 
brain injury that may hinder recruitment. In addition, the 
potential for significant complications from studied treat-
ments may drive away candidate patients. These sugges-
tions are, in part, reflected in our data whereby the 2 high-
est subspecialties for trial discontinuation were epilepsy/
functional neurosurgery (50%) and neurovascular (33%). 
Epilepsy and functional neurosurgery are a small subspe-
cialty within neurosurgery and suffer from difficulties sur-
rounding low caseloads, while conversely the acute nature 
of neurovascular pathologies (aneurysmal subarachnoid 
hemorrhage and malignant middle cerebral artery syn-
drome) may pose obstacles to recruitment. These are im-
portant findings as they highlight some of the challenges 
facing the difficulties for neurosurgical trialists. Without a 
Fig. 4. Chart showing the quality of (a) primary outcome measure and (b) secondary outcome measure reporting by neurosurgi-
cal subspecialty.
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doubt, collaboration (both at the national and international 
level) is vital to ensure that the issues of poor recruitment 
can be tackled in a meaningful and effective manner.
In our cohort of discontinued trials, we found that 5 
(29.4%) had provided results; 2 of these studies were pub-
lished in peer-reviewed articles and a further 3 uploaded 
results to the clinicaltrials.gov database. This gives our 
discontinued trials a nonpublication rate of 88%, which is 
significantly higher than other studies. Kasenda and col-
leagues found a nonpublication rate of 33.6% in a cohort 
of discontinued trials.12 Rosenthal et al. found a nonpub-
lication rate of 45% among their discontinued RCTs.18 
Our higher nonpublication rate can be partly explained 
by our shorter follow-up time compared with the other 
2 studies, both of which focused on a limited timeframe 
(2000–2003). Nonetheless, the high nonpublication rate 
of discontinued trials is equally concerning as data from 
these studies could affect decision-making for patient care. 
One approach to address this data loss is the introduction 
of patient registries that provide continuous data collection 
and monitoring. This has been achieved with good effect 
for devices such as shunts for hydrocephalus. The United 
Kingdom Shunt Registry was established in 1995 and cap-
tures a range of data points on shunt insertion, including 
infection rates. The registry provided strong supportive ev-
idence for the value of antibiotic-impregnated catheters in 
reducing infection rates compared with conventional cath-
eters.16 The success of the registries has led to proposals for 
the expansion of their use within neurosurgery, including 
for implants such as cranioplasties.15
Compared with the discontinued trials, we found that 
completed trials had a lower nonpublication rate (30%). 
The nonpublication rate for neurosurgical RCTs was there-
fore higher compared with the studies of Rosenthal et al. 
(24%) and Chapman et al. (27%).6,18 The difference is small 
and, as previously mentioned, the longer follow-up times 
are a likely contributor to these differences. Similar to 
previous studies, we found that discontinued trials had a 
higher nonpublication rate compared with completed tri-
als.12,18 Interestingly, we found no difference in nonpublica-
tion rate when we compared studies funded by industry 
with those that were not. A number of studies have identi-
fied industry funding to be associated with nonpublication. 
Jones and colleagues investigated large RCTs (500 partici-
pants or more) and found that industry-funded trials had 
a nonpublication rate of 32% compared with only 18% in 
nonindustry-funded trials (p = 0.003).11
Within this study, we were also interested in the quality 
of outcome reporting in the published articles and how this 
compared with the registered outcomes on clinicaltrials.
gov. The CONSORT Group has produced a statement rec-
ommending a minimum amount of data that should be re-
ported by RCTs.2 With respect to neurosurgery, the CON-
SORT reporting standards have been recently assessed by 
Kiehna et al. who concluded that RCT reporting in neu-
rosurgery remains suboptimal.13 Our study demonstrated 
that outcome reporting in neurosurgical RCTs leaves much 
to be desired, with only 61% of trials completely report-
ing primary outcome measures and even lower percent-
ages of complete secondary outcome measure reporting at 
33.3%. These findings, however, compare favorably those 
of a study in a psychology journal evaluating outcome re-
porting that identified 39 registered trials, only 2 of which 
predefined outcome measures and only 1 of which had 
completed outcome reporting at publication.1 Incomplete 
outcome reporting has been quantified in detail by Chan et 
al. who found that in a cohort of 102 trials, 50% of efficacy 
and 45% of harm outcomes were reported completely.5 
They also showed that statistically significant outcomes 
were more likely to be published than nonsignificant out-
comes.
The selection of studies for inclusion in this work from 
a trial registration database means the data loss quantified 
here is almost certainly an underestimate because of prob-
lems that still exist regarding the registration of clinical 
trials. Killeen et al., in a recent analysis of trial registration 
in surgical journals, reported a failure to register trials in 
34.9% of cases (86 trials) and “inadequate” registration in 
21% of cases (52 trials).14 However, the calculated publica-
tion rate of this cohort of studies will likely increase with 
time as completed trials toward the end of the investigated 
period will not have had sufficient time to publish results 
within 2.5 years before our assessment. Support for this is 
evidenced by the time it took some studies to be published. 
An additional limitation was that while the inclusion cri-
teria were defined using registry dates from clinicaltrials.
gov, there was no way to match the inclusion period to a 
PubMed searchable parameter. This meant it was not pos-
sible to obtain information on published trials that should 
have been registered in the study period but were not. The 
number of published but unregistered trials was therefore 
not obtainable.
Conclusions
In this study, we have provided the most comprehen-
sive assessment to date of neurosurgical trial discontinua-
tion and publication outcome. Our analysis highlights that 
more than one-fifth of neurosurgical RCTs are discontin-
ued early and almost a third of those that are completed re-
main unpublished. These findings are consistent with stud-
ies investigating surgical RCTs. However, we found that 
poor recruitment was a disproportionately major driving 
force for the early discontinuation of neurosurgical trials. 
This finding highlights the importance of trialists identify-
ing strategies for improving patient recruitment.
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